Summary The p53 gene is one of the best studied tumour suppressor genes. Recently we performed mutation analysis on the p53 gene in a large number of bone and soft tissue sarcomas, and found that approximately one-third of the sarcomas have some type of DNA alteration at the p53 locus (Toguchida et al., 1992).
Summary The p53 gene is one of the best studied tumour suppressor genes. Recently we performed mutation analysis on the p53 gene in a large number of bone and soft tissue sarcomas, and found that approximately one-third of the sarcomas have some type of DNA alteration at the p53 locus (Toguchida et al., 1992) .
However, the expression of the p53 protein resulting from these alterations still remains to be clarified. In this study, p53 expression in the sarcoma tissues was analysed immunohistochemically using antibody PAb421 (Oncogene Science) and its relationship to DNA alterations was examined. Of 113 tumours, 29 (25.7%) showed positive staining for the p53 protein. These included 19 of 67 osteosarcomas, five of 20 chondrosarcomas, four of 11 malignant fibrous histiocytomas (MFHs) and one Ewing's sarcoma. In chondrosarcoma, most of the p53-positive tumours belonged to highly malignant and atypical tumour types (dedifferentiated or mesenchymal type), suggesting a role for p53 mutation in the progression of cartilaginous tumours. All the cases with a missense mutation showed strongly positive staining, while no immunoreactivity was observed in the remaining three-quarters with DNA alterations including gross rearrangement, frame-shift mutation, nonsense mutation or mutation at splicing site except in one case. These results demonstrated the dominance of the p53 mutations with null protein expression in bone and soft tissue sarcomas, showing a unique characteristic of these types of tumours compared with other malignancies such as colon carcinomas.
The p53 gene, located on chromosome 17p, encodes a 53 kDa nuclear phosphoprotein that has been studied extensively (Levine et al., 1991) . At first p53 was regarded as a tumour antigen because the expression of this gene was observed in SV40-transformed cells (Lane & Crawford, 1979) and the co-transfection of the p53 gene with activated ras oncogene was shown to transform primary rat embryo fibroblasts (Parada et al., 1984) . Later this gene was found to be a tumour-suppressor because p53 with transforming ability was proved to be mutated and reintroduction of a wild-type p53 gene into p53-deficient tumour cells can suppress the neoplastic phenotype (Finlay et al., 1989) . Although the precise biological function of p53 remains to be clarified, alterations of the p53 gene have been observed in a variety of human malignancies including sarcomas (Masuda et al., 1987; Nigro et al., 1989; Stratton et al., 1990; Mulligan et al., 1990) . Recently, we reported the mutation spectrum of the p53 gene in a large number of bone and soft tissue sarcomas, and approximately one-third of sarcomas had some type of DNA alteration (Toguchida et al., 1992) . Of these alterations, onequarter was a missense mutation which was presumed to produce a mutant p53 protein, and the remaining threequarters were other types of DNA alteration such as gross rearrangements, frame-shifts, or nonsense mutations.
It has been reported that although the physiologic concentrations of wild type p53 protein in cells are immunohistochemically undetectable, the increased concentration of the mutated form due to an extended half-life is readily detectable (Rodrigues et al., 1990; Marks et al., 1991) . However, it is not clear whether all the cases with a missense mutation show positive immunoreactivity. It also remains to be clarified how p53 mutations other than missense mutation affect protein expression.
In this study, we analysed immunoreactivity for the p53 protein in various types of bone and soft tissue sarcomas using an antibody to the p53 protein to investigate the 
Discussion
The frequency of p53 positive cases in this study (25.7%) is lower than that of two previous reports (Soini et al., 1992; Dei Tos et al., 1993 (Toguchida et al., 1992) . One-quarter of these mutations consisted of missense mutations at conserved codons in the p53 gene which were presumed to produce a mutant-type p53 protein with an extended half-life. In agreement with this concept, all the tumours with a missense mutation showed positive staining for the p53 protein with relatively strong intensity, although there was a variation in the percentage of positive cells within a tumour. This may be the result of mutational heterogeneity within a tumour or, more likely, due to the different cell-cycle stage of each tumour cell because the immunoreactivity of the p53 protein has been shown to change during the cellcycle (M0rkve et al., 1991) .
We found that 16 of 56 cases with no apparent DNA alteration at the p53 locus showed weak but positive staining for the p53 protein. These tumours may possess some types of mutations, especially missense mutations, which failed to be detected in the initial screening of PCR-SSCP analysis, or were located outside of the analysed regions. However, Western blot analysis of some of these cases showed that the band at 53 kDa detected by PAb421 which recognised both wild and mutant p53, was unable to be detected by a mutantspecific antibody (PAb240, Oncogene Science), (data not shown). This result suggests that the expressed protein is not mutant but wild-type. Wild-type p53 protein, but niot mutant forms, binds to SV40 large T antigen and is overexpressed in SV40-transformed cells (Levine et al., 1991) . Binding to a cellular homologue, such as MDM2 (Oliner et al., 1992) may cause similar overexpression of the wild-type p53.
All tumours with point mutations other than missense mutations, which were predicted to produce no intact p53 protein due to a premature termination codon or abnormal splicing showed negative staining for the p53 protein except one case with one base deletion at codon 112 (KS-131). This frame-shift mutation is predicted to create a premature stop codon downstream at codon 122. However, it might create a new splicing site and produce a mutant p53 protein that can be recognised by the antibody used in this study.
A high frequency of gross rearrangement is one of the unique characteristics of the p53 gene mutations in osteosarcomas (Masuda et al., 1987; Miller et al., 1990) . Because most of these rearrangements take place in intron 1 after the noncoding exon 1, and no structural change was found in the coding region of the p53 gene (Masuda et al., 1987; Miller et al., 1990) , it was unclear how these mutations affect protein , suggesting that the dominant-negative effect of the mutant p53 protein may not be mandatory in the development of sarcomas.
Mutation of the p53 gene is reported to be associated with tumour progression and poor prognosis in some types of human cancers Fults et al., 1992; Mazars et al., 1992; Sameshima et al., 1992; Fujimoto et al., 1992) . Among many types of bone and soft tissue sarcomas, chondrosarcoma is one of the tumours with a clear histological grading, and the clinical prognosis has been shown to be closely associated with this classification (Hearley & Lane, 1986) . In this study, mutations of the p53 gene were found mostly in a high grade tumours (grade III) or atypical chondrosarcomas such as dedifferentiated or mesenchymal types.
Dedifferentiated chondrosarcoma is known to be highly malignant with an ominous prognosis (Capanna et al., 1988) and the prognosis of patients with mesenchymal chondrosarcoma is also rather poor (Nakashima et al., 1986) . These results suggest a role for p53 gene mutation in the progression of chondrosarcoma. The result showing mutational heterogeneity in one dedifferentiated chondrosarcoma case (KS-182) further suggests the importance of the p53 gene in the regulation of differentiation. We have established a tumour cell line from dedifferentiated chondrosarcoma with a missense p53 mutation (Toguchida & Yamaguchi, unpublished data), and it would be intriguing to investigate whether the expression of differentiation markers of chondrosarcoma, such as the type II collagen gene (Benya & Shaffer, 1982) T  G  G  T  G  G  T  G  T  G  A  T  A 
